A number of factors, such as the rising incidence of lifestyle-associated and chronic illnesses, growing aging population, surging patient pool, increasing healthcare spending, growing medical tourism industry, and enhancing healthcare infrastructure, are projected to propel the growth of the embolotherapy market at CAGR of 7.7% during the forecast period (2020–2030). According to P&S Intelligence, the market size is expected to reach $6,447.1 million by 2030 from $3,082.9 million in 2020. Moreover, the market is witnessing a trend of product launches and approvals, across the globe.
Another major driver for the embolotherapy market is the booming geriatric population. Elderly people are more prone to chronic diseases, especially cancer and cardiovascular diseases (CVDs), which is why they account for a high hospitalization rate. Moreover, due to their weak biological functions, many elderly are poor candidates for proper invasive surgeries, as their tissues can take months to heal, as could natural blood coagulation. Therefore, many are now undergoing embolization, as it is a minimally invasive procedure carried out via microcatheters.
The product segment of the embolotherapy market is categorized into support devices and embolic agents. Of these, the embolic agents category generated the higher revenue in 2020, and it is also projected to record the faster growth in the coming years. This can be attributed to the high usage of embolic agents in several interventional radiology procedures. Moreover, the developments of innovative embolic agents, including drug-eluting microspheres, radioactive yttrium-90 (Y-90) microspheres, and calibrated microspheres for bland embolization, for the management of primary and secondary liver diseases, drives the market growth in this category.
Additionally, on the basis of procedure, the embolotherapy market is classified into transcatheter arterial embolization (TAE), transarterial radioembolization (TARE)/selective internal radiation therapy (SIRT), and transarterial chemoembolization (TACE). Among these, the TAE category accounts for the largest market share, and it is also projected to witness the fastest growth during the forecast period. This can be ascribed to the fact that TAE is well-tolerated and effective in patients suffering from ruptured hepatocellular carcinoma (HCC) and due to the increasing requirement for minimally invasive procedures, especially by the surging geriatric population.
Geographically, North America accounted for the largest share in the embolotherapy market in 2020, and it is expected to witness the same trend during the forecast period. This will be due to the rise in the geriatric population, technological advancements, increase in the prevalence of chronic diseases, improvements in the healthcare infrastructure, high disposable income, and development of advanced embolic agents by Stryker Corporation, Guerbet, Sirtex Medical Limited, Terumo Corporation, Meril Life Sciences Pvt. Ltd., Merit Medical Systems Inc., Medtronic Plc, Johnson & Johnson, Kaneka Corporation, Boston Scientific Corporation, and Abbott Laboratories.
Access Report Summary - Embolotherapy Market Global Industry Analysis and Demand Forecast Report @ https://www.psmarketresearch.com/market-analysis/embolotherapy-market
